HS
ADMA icon

HighVista Strategies’s ADMA Biologics ADMA Stock Holding History

HighVista Strategies’s Portfolio ADMA Stock Details ADMA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-95,112
Closed -$1.39M – 146
2025
Q3 		$1.39M Buy
+95,112
New +$1.63M 0.34% 92

Other funds holding ADMA

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
SHCM
Sachem Head Capital Management New York $4.82B AUM 73.38% 1-Year Est. Return
Westfield Capital Management
Westfield Capital Management Boston, Massachusetts $30.6B AUM 61.81% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
Nuveen
Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return

HighVista Strategies's ADMA Position: Q4 2025 in Review

HighVista Strategies sold out of ADMA Biologics (ADMA) in Q4 2025, closing a stake of 95,112 shares — an estimated $1.39M sold.

HighVista Strategies first reported a position in ADMA in Q3 2025 and held it in 1 quarter. The position peaked at $1.39M in Q3 2025. 356 funds tracked by Wall St. Rank hold ADMA as of Q4 2025.

  • HighVista Strategies reported no remaining ADMA Biologics position as of Q4 2025 after selling out during the quarter.
  • HighVista Strategies sold 95,112 ADMA Biologics shares in Q4 2025, an estimated $1.39M.
  • HighVista Strategies first reported a position in ADMA Biologics in Q3 2025 and held it in 1 quarter.
  • HighVista Strategies's ADMA Biologics position peaked at $1.39M in Q3 2025.
  • 356 funds tracked by Wall St. Rank held ADMA Biologics as of Q4 2025.

Based on HighVista Strategies's 13F filing for Q4 2025, filed 17 Feb 2026.